FOR IMMEDIATE RELEASE
New Leadership Elected for Prestigious Medical Society
(WASHINGTON, November 2, 2006) – The American Society of Hematology (ASH™), the world’s largest professional society of blood specialists, welcomes four new officers to its Executive Committee, the governing body of the organization. The officers will begin their positions in January 2007.
Nancy Berliner, MD, will serve a one-year term as vice president, followed by successive terms as president-elect and president. Linda Burns, MD, elected treasurer, will serve a four-year term overseeing the financial concerns of the Society, and new councillors Brian Druker, MD, and D. Gary Gilliland, MD, PhD, will also serve four years. These individuals are well-respected hematologists and active members of the Society.
Dr. Berliner has served on the ASH Program Committee, which oversees the ASH annual meeting, is a veteran of the Executive Committee, having served as secretary from 2001-2004, and is currently the editor of Hematology, the ASH Education Program Book. She is currently Professor of Internal Medicine and Genetics at Yale Medical School and will assume the position of Chief of Hematology at the Brigham and Women’s Hospital in January 2007.
Dr. Burns, Associate Professor of Medicine and Fellowship Director of the Hematology, Oncology, and Transplantation Program at the University of Minnesota, has been actively involved in hematology training issues for several years, participating in the Society’s Trainee Council and Committee on Training Programs, currently serving as its chair; and as a faculty member of the ASH Clinical Training Research Institute. In addition, she serves on the ASH Program Committee.
Dr. Druker, well known for the development of the cancer drug Gleevec, received the William Dameshek Prize – one of the Society’s highest honors – in 2001, and is currently an associate editor of Blood, ASH’s scientific journal. Dr. Druker is the JELD-WEN Chair of Leukemia Research at Oregon Health and Science University Cancer Institute and an Investigator of the Howard Hughes Medical Institute.
Also a Dameshek Prize recipient, Dr. Gilliland has served on the ASH Program Committee and Scientific Committee on Neoplasia, and currently serves on the Awards Committee. He is Professor of Medicine at Brigham and Women's Hospital and Harvard Medical School, an Investigator of the Howard Hughes Medical Institute, Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center, and Director of the Cancer Stem Cell Program of the Harvard Stem Cell Institute.
Back to Press Release Listing
|
